Overview

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

Status:
Active, not recruiting

Trial end date:
2022-12-13

Target enrollment:

Participant gender:

Summary

Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population). Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Azacitidine
Cytarabine
Daunorubicin